Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 120 of 120 entries
Sorted by: Best Match Show Resources per page
Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas.

Veterinary and comparative oncology

Azuma K, Ohmi A, Goto-Koshino Y, Tomiyasu H, Ohno K, Chambers JK, Uchida K, Namba H, Nagata M, Nagamine E, Nibe K, Irie M, Tsujimoto H.
PMID: 34250731
Vet Comp Oncol. 2021 Jul 11; doi: 10.1111/vco.12752. Epub 2021 Jul 11.

Canine cutaneous lymphoma is an uncommon lymphoma in dogs. Most canine cutaneous lymphoma cases have a T-cell origin. Canine cutaneous T-cell lymphoma (CTCL) is classified into epitheliotropic and nonepitheliotropic cutaneous lymphomas, and each type of lymphoma is subclassified into...

Cite
Azuma K, Ohmi A, Goto-Koshino Y, et al. Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas. Vet Comp Oncol. 2021;doi: 10.1111/vco.12752.
Azuma, K., Ohmi, A., Goto-Koshino, Y., Tomiyasu, H., Ohno, K., Chambers, J. K., Uchida, K., Namba, H., Nagata, M., Nagamine, E., Nibe, K., Irie, M., & Tsujimoto, H. (2021). Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas. Veterinary and comparative oncology, . https://doi.org/10.1111/vco.12752
Azuma, Kazushi, et al. "Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas." Veterinary and comparative oncology vol. (2021). doi: https://doi.org/10.1111/vco.12752
Azuma K, Ohmi A, Goto-Koshino Y, Tomiyasu H, Ohno K, Chambers JK, Uchida K, Namba H, Nagata M, Nagamine E, Nibe K, Irie M, Tsujimoto H. Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas. Vet Comp Oncol. 2021 Jul 11; doi: 10.1111/vco.12752. Epub 2021 Jul 11. PMID: 34250731.
Copy Download .nbib Format: NLM
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.

Critical reviews in oncology/hematology

Fazzari FGT, Rose F, Pauls M, Guay E, Ibrahim MFK, Basulaiman B, Megan T, Hutton B, Nicholas G, Ng TL, Bourgeau K.
PMID: 34808376
Crit Rev Oncol Hematol. 2021 Nov 19;103540. doi: 10.1016/j.critrevonc.2021.103540. Epub 2021 Nov 19.

AIM: Conduct a systematic review of the effectiveness of systemic therapies for adult recurrent glioblastoma (rGBM).METHODS: We electronically searched for randomized controlled trials from three major databases and four conferences from 2009-Dec 2020. Two independent reviewers conducted screening, data...

Cite
Fazzari FGT, Rose F, Pauls M, et al. The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Crit Rev Oncol Hematol. 2021;103540doi: 10.1016/j.critrevonc.2021.103540.
Fazzari, F. G. T., Rose, F., Pauls, M., Guay, E., Ibrahim, M. F. K., Basulaiman, B., Megan, T., Hutton, B., Nicholas, G., Ng, T. L., & Bourgeau, K. (2021). The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Critical reviews in oncology/hematology, 103540. https://doi.org/10.1016/j.critrevonc.2021.103540
Fazzari, Francesco G T, et al. "The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials." Critical reviews in oncology/hematology vol. (2021): 103540. doi: https://doi.org/10.1016/j.critrevonc.2021.103540
Fazzari FGT, Rose F, Pauls M, Guay E, Ibrahim MFK, Basulaiman B, Megan T, Hutton B, Nicholas G, Ng TL, Bourgeau K. The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Crit Rev Oncol Hematol. 2021 Nov 19;103540. doi: 10.1016/j.critrevonc.2021.103540. Epub 2021 Nov 19. PMID: 34808376.
Copy Download .nbib Format: NLM
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.

Critical reviews in oncology/hematology

Fazzari FGT, Rose F, Pauls M, Guay E, Ibrahim MFK, Basulaiman B, Tu M, Hutton B, Nicholas G, Ng TL.
PMID: 34808376
Crit Rev Oncol Hematol. 2021 Nov 19;169:103540. doi: 10.1016/j.critrevonc.2021.103540. Epub 2021 Nov 19.

AIM: Conduct a systematic review of the effectiveness of systemic therapies for adult recurrent glioblastoma (rGBM).METHODS: We electronically searched for randomized controlled trials from three major databases and four conferences from 2009-Dec 2020. Two independent reviewers conducted screening, data...

Cite
Fazzari FGT, Rose F, Pauls M, et al. The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Crit Rev Oncol Hematol. 2021;169:103540doi: 10.1016/j.critrevonc.2021.103540.
Fazzari, F. G. T., Rose, F., Pauls, M., Guay, E., Ibrahim, M. F. K., Basulaiman, B., Tu, M., Hutton, B., Nicholas, G., & Ng, T. L. (2021). The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Critical reviews in oncology/hematology, 169103540. https://doi.org/10.1016/j.critrevonc.2021.103540
Fazzari, Francesco G T, et al. "The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials." Critical reviews in oncology/hematology vol. 169 (2021): 103540. doi: https://doi.org/10.1016/j.critrevonc.2021.103540
Fazzari FGT, Rose F, Pauls M, Guay E, Ibrahim MFK, Basulaiman B, Tu M, Hutton B, Nicholas G, Ng TL. The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Crit Rev Oncol Hematol. 2021 Nov 19;169:103540. doi: 10.1016/j.critrevonc.2021.103540. Epub 2021 Nov 19. PMID: 34808376.
Copy Download .nbib Format: NLM
Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma.

Translational oncology

Sundar SJ, Shakya S, Barnett A, Wallace LC, Jeon H, Sloan A, Recinos V, Hubert CG.
PMID: 34700192
Transl Oncol. 2021 Oct 23;15(1):101251. doi: 10.1016/j.tranon.2021.101251. Epub 2021 Oct 23.

BACKGROUND: Glioblastoma (GBM) is the most common primary brain tumor with a dismal prognosis. The inherent cellular diversity and interactions within tumor microenvironments represent significant challenges to effective treatment. Traditional culture methods such as adherent or sphere cultures may...

Cite
Sundar SJ, Shakya S, Barnett A, et al. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl Oncol. 2021;15(1):101251doi: 10.1016/j.tranon.2021.101251.
Sundar, S. J., Shakya, S., Barnett, A., Wallace, L. C., Jeon, H., Sloan, A., Recinos, V., & Hubert, C. G. (2021). Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Translational oncology, 15(1), 101251. https://doi.org/10.1016/j.tranon.2021.101251
Sundar, Swetha J, et al. "Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma." Translational oncology vol. 15,1 (2021): 101251. doi: https://doi.org/10.1016/j.tranon.2021.101251
Sundar SJ, Shakya S, Barnett A, Wallace LC, Jeon H, Sloan A, Recinos V, Hubert CG. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl Oncol. 2021 Oct 23;15(1):101251. doi: 10.1016/j.tranon.2021.101251. Epub 2021 Oct 23. PMID: 34700192; PMCID: PMC8551697.
Copy Download .nbib Format: NLM
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients.

Neuro-oncology advances

Gerstner ER, Emblem KE, Yen YF, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker JM, Duda DG, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT.
PMID: 33392506
Neurooncol Adv. 2020 Nov 17;2(1):vdaa157. doi: 10.1093/noajnl/vdaa157. eCollection 2020.

BACKGROUND: Hypoxia is a driver of treatment resistance in glioblastoma. Antiangiogenic agents may transiently normalize blood vessels and decrease hypoxia before excessive pruning of vessels increases hypoxia. The time window of normalization is dose and time dependent. We sought...

Cite
Gerstner ER, Emblem KE, Yen YF, et al. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020;2(1):vdaa157doi: 10.1093/noajnl/vdaa157.
Gerstner, E. R., Emblem, K. E., Yen, Y. F., Dietrich, J., Jordan, J. T., Catana, C., Wenchin, K. L., Hooker, J. M., Duda, D. G., Rosen, B. R., Kalpathy-Cramer, J., Jain, R. K., & Batchelor, T. T. (2020). Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-oncology advances, 2(1), vdaa157. https://doi.org/10.1093/noajnl/vdaa157
Gerstner, Elizabeth R, et al. "Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients." Neuro-oncology advances vol. 2,1 (2020): vdaa157. doi: https://doi.org/10.1093/noajnl/vdaa157
Gerstner ER, Emblem KE, Yen YF, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker JM, Duda DG, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020 Nov 17;2(1):vdaa157. doi: 10.1093/noajnl/vdaa157. eCollection 2020. PMID: 33392506; PMCID: PMC7764510.
Copy Download .nbib Format: NLM
Clinicopathologic, immunohistochemical, and ultrastructural features of histiocytic sarcoma in a chinchilla (Chinchilla lanigera).

Veterinary medicine and science

Enomoto K, Tsutsumitani C, Asakawa MG.
PMID: 34587369
Vet Med Sci. 2021 Sep 29; doi: 10.1002/vms3.645. Epub 2021 Sep 29.

A 9-year-old intact female chinchilla (Chinchilla lanigera) was presented to a referring veterinarian due to small, multiple cervical nodules that had been rapidly increasing in size and number. Cytology of the nodules revealed sheets of pleomorphic round cells that...

Cite
Enomoto K, Tsutsumitani C, Asakawa MG. Clinicopathologic, immunohistochemical, and ultrastructural features of histiocytic sarcoma in a chinchilla (Chinchilla lanigera). Vet Med Sci. 2021;doi: 10.1002/vms3.645.
Enomoto, K., Tsutsumitani, C., & Asakawa, M. G. (2021). Clinicopathologic, immunohistochemical, and ultrastructural features of histiocytic sarcoma in a chinchilla (Chinchilla lanigera). Veterinary medicine and science, . https://doi.org/10.1002/vms3.645
Enomoto, Kaoru, et al. "Clinicopathologic, immunohistochemical, and ultrastructural features of histiocytic sarcoma in a chinchilla (Chinchilla lanigera)." Veterinary medicine and science vol. (2021). doi: https://doi.org/10.1002/vms3.645
Enomoto K, Tsutsumitani C, Asakawa MG. Clinicopathologic, immunohistochemical, and ultrastructural features of histiocytic sarcoma in a chinchilla (Chinchilla lanigera). Vet Med Sci. 2021 Sep 29; doi: 10.1002/vms3.645. Epub 2021 Sep 29. PMID: 34587369.
Copy Download .nbib Format: NLM
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

The Cochrane database of systematic reviews

McBain C, Lawrie TA, Rogozińska E, Kernohan A, Robinson T, Jefferies S.
PMID: 34559423
Cochrane Database Syst Rev. 2021 May 04;5:CD013579. doi: 10.1002/14651858.CD013579.pub2.

BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumour that almost inevitably progresses or recurs after first line standard of care. There is no consensus regarding the best treatment/s to offer people upon disease progression or recurrence. For the...

Cite
McBain C, Lawrie TA, Rogozińska E, et al. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021;5:CD013579doi: 10.1002/14651858.CD013579.pub2.
McBain, C., Lawrie, T. A., Rogozińska, E., Kernohan, A., Robinson, T., & Jefferies, S. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. The Cochrane database of systematic reviews, 5CD013579. https://doi.org/10.1002/14651858.CD013579.pub2
McBain, Catherine, et al. "Treatment options for progression or recurrence of glioblastoma: a network meta-analysis." The Cochrane database of systematic reviews vol. 5 (2021): CD013579. doi: https://doi.org/10.1002/14651858.CD013579.pub2
McBain C, Lawrie TA, Rogozińska E, Kernohan A, Robinson T, Jefferies S. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021 May 04;5:CD013579. doi: 10.1002/14651858.CD013579.pub2. PMID: 34559423; PMCID: PMC8121043.
Copy Download .nbib Format: NLM
Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma.

Translational oncology

Sundar SJ, Shakya S, Barnett A, Wallace LC, Jeon H, Sloan A, Recinos V, Hubert CG.
PMID: 34700192
Transl Oncol. 2021 Oct 23;15(1):101251. doi: 10.1016/j.tranon.2021.101251. Epub 2021 Oct 23.

BACKGROUND: Glioblastoma (GBM) is the most common primary brain tumor with a dismal prognosis. The inherent cellular diversity and interactions within tumor microenvironments represent significant challenges to effective treatment. Traditional culture methods such as adherent or sphere cultures may...

Cite
Sundar SJ, Shakya S, Barnett A, et al. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl Oncol. 2021;15(1):101251doi: 10.1016/j.tranon.2021.101251.
Sundar, S. J., Shakya, S., Barnett, A., Wallace, L. C., Jeon, H., Sloan, A., Recinos, V., & Hubert, C. G. (2021). Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Translational oncology, 15(1), 101251. https://doi.org/10.1016/j.tranon.2021.101251
Sundar, Swetha J, et al. "Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma." Translational oncology vol. 15,1 (2021): 101251. doi: https://doi.org/10.1016/j.tranon.2021.101251
Sundar SJ, Shakya S, Barnett A, Wallace LC, Jeon H, Sloan A, Recinos V, Hubert CG. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl Oncol. 2021 Oct 23;15(1):101251. doi: 10.1016/j.tranon.2021.101251. Epub 2021 Oct 23. PMID: 34700192; PMCID: PMC8551697.
Copy Download .nbib Format: NLM
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.

Scientific reports

Lavogina D, Laasfeld T, Vardja M, Lust H, Jaal J.
PMID: 34645858
Sci Rep. 2021 Oct 13;11(1):20338. doi: 10.1038/s41598-021-99630-0.

Despite the use of multimodal treatment combinations, the prognosis of glioblastoma (GB) is still poor. To prevent rapid tumor recurrence, targeted strategies for the treatment of GB are widely sought. Here, we compared the efficacy of focused modulation of...

Cite
Lavogina D, Laasfeld T, Vardja M, et al. Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets. Sci Rep. 2021;11(1):20338doi: 10.1038/s41598-021-99630-0.
Lavogina, D., Laasfeld, T., Vardja, M., Lust, H., & Jaal, J. (2021). Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets. Scientific reports, 11(1), 20338. https://doi.org/10.1038/s41598-021-99630-0
Lavogina, Darja, et al. "Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets." Scientific reports vol. 11,1 (2021): 20338. doi: https://doi.org/10.1038/s41598-021-99630-0
Lavogina D, Laasfeld T, Vardja M, Lust H, Jaal J. Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets. Sci Rep. 2021 Oct 13;11(1):20338. doi: 10.1038/s41598-021-99630-0. PMID: 34645858; PMCID: PMC8514540.
Copy Download .nbib Format: NLM
Multifocal high-grade glioma radiotherapy safety and efficacy.

Radiation oncology (London, England)

Fleischmann DF, Schön R, Corradini S, Bodensohn R, Hadi I, Hofmaier J, Forbrig R, Thon N, Dorostkar M, Belka C, Niyazi M.
PMID: 34454558
Radiat Oncol. 2021 Aug 28;16(1):165. doi: 10.1186/s13014-021-01886-3.

BACKGROUND: Multifocal manifestation of high-grade glioma is a rare disease with very unfavourable prognosis. The pathogenesis of multifocal glioma and pathophysiological differences to unifocal glioma are not fully understood. The optimal treatment of patients suffering from multifocal high-grade glioma...

Cite
Fleischmann DF, Schön R, Corradini S, et al. Multifocal high-grade glioma radiotherapy safety and efficacy. Radiat Oncol. 2021;16(1):165doi: 10.1186/s13014-021-01886-3.
Fleischmann, D. F., Schön, R., Corradini, S., Bodensohn, R., Hadi, I., Hofmaier, J., Forbrig, R., Thon, N., Dorostkar, M., Belka, C., & Niyazi, M. (2021). Multifocal high-grade glioma radiotherapy safety and efficacy. Radiation oncology (London, England), 16(1), 165. https://doi.org/10.1186/s13014-021-01886-3
Fleischmann, Daniel Felix, et al. "Multifocal high-grade glioma radiotherapy safety and efficacy." Radiation oncology (London, England) vol. 16,1 (2021): 165. doi: https://doi.org/10.1186/s13014-021-01886-3
Fleischmann DF, Schön R, Corradini S, Bodensohn R, Hadi I, Hofmaier J, Forbrig R, Thon N, Dorostkar M, Belka C, Niyazi M. Multifocal high-grade glioma radiotherapy safety and efficacy. Radiat Oncol. 2021 Aug 28;16(1):165. doi: 10.1186/s13014-021-01886-3. PMID: 34454558; PMCID: PMC8400399.
Copy Download .nbib Format: NLM
Current FDA-Approved Therapies for High-Grade Malignant Gliomas.

Biomedicines

Fisher JP, Adamson DC.
PMID: 33810154
Biomedicines. 2021 Mar 22;9(3). doi: 10.3390/biomedicines9030324.

The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months. Before this SOC was established, glioblastoma (GBM)...

Cite
Fisher JP, Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines. 2021;9(3)doi: 10.3390/biomedicines9030324.
Fisher, J. P., & Adamson, D. C. (2021). Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines, 9(3), . https://doi.org/10.3390/biomedicines9030324
Fisher, Jacob P, and Adamson, David C. "Current FDA-Approved Therapies for High-Grade Malignant Gliomas." Biomedicines vol. 9,3 (2021). doi: https://doi.org/10.3390/biomedicines9030324
Fisher JP, Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines. 2021 Mar 22;9(3). doi: 10.3390/biomedicines9030324. PMID: 33810154; PMCID: PMC8004675.
Copy Download .nbib Format: NLM
Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review.

Cureus

Irfan N, Samuel E, Rafi Ranjha F, Waheed A, Abu Bakar M, Usman S, Butt S, Rashid A, Yousaf I.
PMID: 33224664
Cureus. 2020 Oct 20;12(10):e11070. doi: 10.7759/cureus.11070.

Background The role of Procarbazine Lomustine and Vincristine (PCV) chemotherapy is already established in terms of improving survival in low-grade glioma (LGG). This improved survival has led to the increasing administration of PCV to LGG patients over the past...

Cite
Irfan N, Samuel E, Rafi Ranjha F, et al. Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review. Cureus. 2020;12(10):e11070doi: 10.7759/cureus.11070.
Irfan, N., Samuel, E., Rafi Ranjha, F., Waheed, A., Abu Bakar, M., Usman, S., Butt, S., Rashid, A., & Yousaf, I. (2020). Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review. Cureus, 12(10), e11070. https://doi.org/10.7759/cureus.11070
Irfan, Nabia, et al. "Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review." Cureus vol. 12,10 (2020): e11070. doi: https://doi.org/10.7759/cureus.11070
Irfan N, Samuel E, Rafi Ranjha F, Waheed A, Abu Bakar M, Usman S, Butt S, Rashid A, Yousaf I. Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review. Cureus. 2020 Oct 20;12(10):e11070. doi: 10.7759/cureus.11070. PMID: 33224664; PMCID: PMC7676953.
Copy Download .nbib Format: NLM
Showing 109 to 120 of 120 entries